1. Methylnaltrexone in the Treatment of Opioid-Induced Constipation in Cancer Patients Receiving Palliative Care: Willingness-to-Pay and Cost-Benefit Analysis 
Michael Iskedjian, BPharm, MSc, Shrividya Iyer, PhD, S. Lawrence Librach, MD, CCFP, FCFP, Mike Wang, BSc, Bechara Farah, MSc, Jade Berbari, BSc 
Journal of Pain and Symptom Management 
Volume 41, Issue 1, Pages (January 2011)
DOI: /j.jpainsymman
Copyright © 2011 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1
Decision board presenting a palliative state, the opioid-induced constipation associated to it, and both treatment options for it.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2011 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2
Diagram illustrating the framework of the cost-benefit analysis. MNTX=methylnaltrexone; N=number.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2011 U.S. Cancer Pain Relief Committee Terms and Conditions

4. Fig. 3
Results of the Monte Carlo simulation presenting the willingness to pay vs. the cost of the resources. NB: The diagonal line represents the break-even line, with results to the top left displaying that methylnaltrexone is the option of choice (i.e., providing a cost benefit). An equation defining the line is provided.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2011 U.S. Cancer Pain Relief Committee Terms and Conditions